Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
5(100.0%)
5Total
N/A(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05591989Not ApplicableCompleted

Clinical Evaluation of Safety and Efficacy for the NEUROMARK System in Subjects With Chronic Rhinitis (PARAGON)

Role: lead

NCT05937308Not ApplicableActive Not Recruiting

NEUROMARK Registry Study

Role: lead

NCT06128200Not ApplicableCompleted

NEUROMARK Randomized Controlled Trial

Role: lead

NCT05324397Not ApplicableCompleted

Safety and Efficacy Study of the Neurent Medical NEUROMARK™ System in Subjects With Chronic Rhinitis (CLARITY)

Role: lead

NCT04769596Not ApplicableCompleted

Safety and Efficacy Study of the Neurent Medical NEUROMARK™ System in Subjects With Chronic Rhinitis

Role: lead

All 5 trials loaded